Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564275 | 0.82 | SLC6A2 (0.52) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL25596207 | 0.82 | ESR1 (0.59) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL13599422 | 0.82 | SLC6A2 (0.57) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL1555419 | 0.82 | SLC6A2 (0.47) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL18883609 | 0.79 | SKP2 (0.39) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL2779893 | 0.79 | SLC6A4 (0.44) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL27207974 | 0.79 | SLC6A2 (0.44) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL14944886 | 0.79 | SLC6A2 (0.44) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL5514588 | 0.79 | CRHBP (0.49) | SLC6A2HTR2AHTR2BSLC6A4HRH1 | |
| SCHEMBL26391639 | 0.78 | ALDH1A1 (0.39) | SLC6A2HTR2AHTR2BSLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039514-B2 | Sulfonamide compounds and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8039514-B2 | Sulfonamide compounds and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2292592-A1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| WO-2009148052-A1 | SULFONAMIDE COMPOUND AND APPLICATION THEREOF | 旭化成ファーマ株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | SLC6A2 1690/4885HTR2A 2600/4885HTR2B 2649/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | SLC6A2 1690/4885HTR2A 2600/4885HTR2B 2649/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | SLC6A2 1481/4885HTR2A 2663/4885HTR2B 2749/4885 |
| US-20100022601-A1 | SULFONAMIDE COMPOUNDS AND THE USE | PTH1R, CASR, SOST | SLC6A2 3750/4885HTR2A 3685/4885HTR2B 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.